XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 25, 2022
Jun. 26, 2021
Operating activities:    
Net earnings $ 29,925,000 $ 36,732,000
Adjustments to reconcile net earnings to net cash (used in) provided by operating activities:    
Depreciation of fixed assets 36,292,000 36,278,000
Amortization of intangibles and deferred costs 1,775,000 2,096,000
Loss from disposals of property & equipment 50,000 0
Share-based compensation 3,484,000 3,252,000
Deferred income taxes (227,000) (188,000)
Loss (Gain) on marketable securities 412,000 (926,000)
Other (212,000) (305,000)
Changes in assets and liabilities net of effects from purchase of companies    
Increase in accounts receivable (78,058,000) (27,940,000)
Increase in inventories (42,784,000) (5,964,000)
(Increase) decrease in prepaid expenses (102,000) 5,710,000
Increase in accounts payable and accrued liabilities 19,798,000 24,823,000
Net cash (used in) provided by operating activities (29,647,000) 73,568,000
Investing activities:    
Payments for purchases of companies, net of cash acquired (221,301,000) 0
Purchases of property, plant and equipment (64,231,000) (34,456,000)
Proceeds from redemption and sales of marketable securities 11,526,000 54,191,000
Proceeds from disposal of property and equipment 1,147,000 2,079,000
Other 0 42,000
Net cash (used in) provided by investing activities (272,859,000) 21,856,000
Financing activities:    
Proceeds from issuance of stock 12,168,000 17,178,000
Borrowings under credit facility 125,000,000 0
Payments for debt issue costs (225,000) 0
Payments on finance lease obligations (150,000) (48,000)
Payment of cash dividend (36,299,000) (32,719,000)
Net cash provided by (used in) financing activities 100,494,000 (15,589,000)
Effect of exchange rate on cash and cash equivalents 103,000 624,000
Net (decrease) increase in cash and cash equivalents (201,909,000) 80,459,000
Cash and cash equivalents at beginning of period 283,192,000 195,809,000
Cash and cash equivalents at end of period $ 81,283,000 $ 276,268,000